COVID19 (disease)
Moderna CEO Reflects on 2024 Challenges and Advances in Shareholder Letter
Moderna, shareholder letter, 2024 review, RSV vaccine, COVID-19 vaccine, mRNA medicines, Stéphane Bancel
BioNTech Resolves COVID-19 Vaccine Royalty Disputes with NIH and UPenn
BioNTech, COVID-19 vaccine, royalty disputes, NIH, UPenn, Pfizer, settlement agreements
Controversial Stanford Professor Jay Bhattacharya Nominated by Trump to Lead NIH Amid Criticism Over Pandemic Views
Jay Bhattacharya, NIH Director Nomination, COVID-19 Pandemic Response Critic, Stanford University Professor, Trump Administration, Public Health Research, Controversial Appointment
Moderna’s COVID-19 Vaccine Sales Exceed Expectations, but RSV Vaccine Falls Short
Moderna, COVID-19 vaccine, RSV vaccine, vaccine sales, pharmaceutical industry
Coherus Resumes Biosimilar Supply Following Temporary Disruption; Novavax Terminates COVID-19 Vaccine Deal with UK
Coherus BioSciences, Biosimilar supply, UDENYCA, Supply chain issues, Novavax, COVID-19 vaccine deal, UK
Gilead Exceeds COVID-19 Drug Sales Projections, Faces $1.75 Billion Loss on Trodelvy Trial Failure
Gilead, COVID-19, Veklury, Trodelvy, drug sales, clinical trial failure
BioNTech Beats Q3 Expectations but Trims Full-Year Revenue Guidance Amid COVID-19 Vaccine Sales
BioNTech, Q3 earnings, COVID-19 vaccine, Revenue guidance, Oncology development, mRNA-based immunotherapies
Pfizer Boosts Revenue Forecast by $1.5 Billion Amid Paxlovid Rebound, Despite Criticism from Starboard
Pfizer, revenue outlook, Paxlovid, Starboard, pharmaceuticals, COVID-19, financial performance
FDA Places Clinical Hold on Novavax’s COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates Due to Rare Adverse Event
Novavax, FDA, COVID-19, Influenza, Vaccine, Clinical Hold, Motor Neuropathy
FDA Places Clinical Hold on Novavax’s COVID-19-Influenza Combination and Standalone Influenza Vaccine Trials
Novavax, FDA, Clinical Hold, COVID-19, Influenza, Vaccine Trials, Motor Neuropathy